Capital One
COF
$201.34
-1.03%
Capital One Financial is a diversified financial services holding company whose core business is credit card lending, supplemented by consumer banking (including auto loans) and commercial lending; credit cards generate the majority of revenue, and the 2025 acquisition of Discover added a card network and a modest personal loan business. Capital One is best characterized as a scaled, data-driven consumer lender and one of the largest card issuers in the U.S., now attempting to evolve into a network-integrated payments platform through Discover rather than a pure balance-sheet lender. The investor narrative is dominated by the Discover integration — management is targeting cost savings and revenue synergies that bulls argue could lift earnings roughly 15% by 2027 — set against a messy reported earnings picture from acquisition accounting, a Q1 2026 estimate miss, and a stock that has badly lagged the market. A secondary debate centers on consumer credit: subprime auto delinquencies at 32-year highs are pressuring riskier lenders, and investors are parsing whether Capital One's disciplined underwriting is a relative advantage or a warning that loss provisions will stay elevated.…
COF
Capital One
$201.34
Related headlines
Investment Opinion: Should I buy COF Today?
Rating: Buy (speculative value with catalyst). The core thesis is that Capital One trades at 8.38x forward earnings and 1.15x book — a 40-50% discount to financials peers — while consensus 2027 EPS of $37.23 and an average analyst target of $252.27 (+25.0% upside) imply the market is overly pessimistic about Discover integration and credit quality. The consensus recommendation is "buy" (mean 1.625), with all 22 analysts holding targets above the current price.
Supporting evidence: (1) Revenue grew 21.03% year-over-year in Q2 2026 to $19.861 billion, with quarterly net income of $3.020 billion (EPS $4.73) versus a year-ago loss; (2) forward PE of 8.38x versus trailing 60.1x shows the market expects earnings to multiply as synergies land; (3) price-to-book of 1.15x sits mid-range of the stock's own 0.91x-1.35x band, not distressed but far from premium; (4) trailing free cash flow of $32.199 billion against a $131.0 billion market cap implies a ~24.6% FCF yield, and the 1.35% dividend yield is covered by a 0.72 payout ratio. The implied upside to the average target is 25.0%, and even the lowest target ($219) is 8.6% above the current price.
Risks and conditions: The biggest risks are (1) consumer credit deterioration — subprime auto delinquencies at 32-year highs could force provision builds that erase the earnings recovery; (2) Discover integration execution — the Q1 2026 estimate miss shows how quickly sentiment can sour; (3) valuation compression if 2027 EPS estimates are cut. This Buy would downgrade to Hold if forward PE rises above 12x without corresponding EPS upgrades, or if credit costs push net charge-offs above pre-acquisition levels. It would upgrade to Strong Buy if the stock breaks above the $220-$228 resistance area on evidence of synergy delivery. Verdict: undervalued relative to forward earnings and peers, but fairly valued relative to its own recent book-value history — the discount is justified by execution risk, making this a high-risk, high-reward value play rather than a deep-value bargain.
Sign up to view all
COF 12-Month Price Forecast
The forward-looking view is balanced: the valuation (8.38x forward PE, 1.15x book) and unanimous analyst upside (25.0% to average target) argue for a bullish stance, but the persistent downtrend (-18.63% YTD, -30.56 relative strength) and depressed trailing profitability (ROE 2.16%) justify caution. The base case (50% probability) targets $219-$252, implying 8.6-25.0% upside as earnings normalize, while the bear case (20%) risks a retest of $174.24. I would upgrade to bullish if Q3 2026 earnings show synergy capture and credit stabilization, or downgrade to bearish if net charge-offs rise and 2027 EPS estimates are cut below $36.27. The key tension is timing: the stock is cheap on forward earnings, but the market needs proof that the Discover integration and credit quality are on track before re-rating.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Capital One's 12-month outlook, with a consensus price target around $254.55 and implied upside of +26.4% versus the current price.
Average Target
$254.55
0 analysts
Implied Upside
+26.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$220 - $290
Analyst target range
Coverage is robust, with 22 analysts and a consensus recommendation of "buy" (mean rating 1.625 on a 1–5 scale where 1 is a strong buy). The average target price of $252.27 implies roughly +25.0% upside from the current $201.74, and notably even the lowest target of $219.00 sits about 8.6% above the current price — meaning no covering analyst sees downside from here. Consensus 2027 EPS of $37.23 (range $36.27–$37.99) and revenue of $77.72 billion (range $76.19–$78.94 billion) underpin that bullish stance, and the tight EPS range signals high confidence in the earnings trajectory.
The target range of $219.00 to $290.00 is moderately wide — a 32% spread from low to high — reflecting genuine uncertainty about Discover synergy realization and credit costs rather than disagreement about the business model. The $290 high target implies roughly 44% upside and would require both multiple expansion toward 1.5x+ book and full delivery of the 15% earnings uplift from Discover integration; the $219 low target essentially prices in only modest synergy capture and continued credit normalization. Institutional ratings show a clear pattern of stability and selective upgrades: HSBC moved from Hold to Buy on July 13, 2026, and Piper Sandler, Wolfe Research, UBS, Citigroup, Evercore ISI, Barclays, JP Morgan, B of A, and TD Cowen all reiterated Buy/Overweight/Outperform ratings between July and September 2026 with no downgrades — a strong signal that the sell-side views the recent underperformance as an entry opportunity rather than a deterioration in fundamentals.
Drowning in data?
Find the real signal!
Bulls vs Bears: COF Investment Factors
The bear case currently has stronger near-term evidence: the stock has lost 18.63% YTD, underperforms the market by 30.56 percentage points, and trailing profitability metrics (ROE 2.16%, net margin 3.54%) remain deeply depressed. However, the bull case rests on forward fundamentals that are unusually well-supported — consensus 2027 EPS of $37.23 with a tight $36.27-$37.99 range, an 8.38x forward PE, and unanimous analyst targets above the current price. The single most important tension is whether the Discover synergy-driven earnings recovery is real and timely: if 2027 EPS of $37+ is achieved, the stock is dramatically undervalued at 8.38x forward earnings, but if credit costs rise and integration slips, book value near 1.15x becomes the floor. The market is currently voting bearish on execution, while the sell-side is voting bullish on fundamentals — a classic disconnect that will resolve on the next few earnings reports.
Bullish
- Deep valuation discount to peers: At 8.38x forward PE and 1.15x price-to-book, Capital One trades at roughly a 40-50% discount to the broader financials sector's mid-teens multiple and below the 1.5-2.0x book typically awarded to high-quality consumer lenders. This discount embeds significant pessimism that could unwind if Discover synergies materialize.
- Discover synergies could lift EPS 15%: Management targets cost savings and revenue synergies from the Discover acquisition that bulls argue could boost earnings roughly 15% by 2027. Consensus 2027 EPS of $37.23 (tight range $36.27-$37.99) implies earnings more than double the current quarterly run-rate, and the tight analyst range signals high confidence in this trajectory.
- Revenue growth accelerating post-acquisition: Q2 2026 revenue of $19.861 billion grew 21.03% year-over-year, following 44.1% growth in Q1 2026 and 42.0% in Q4 2025. The step-change from ~$13.4-13.8 billion pre-deal to ~$19.3-19.9 billion post-deal demonstrates the scale benefit of Discover, with credit card revenue at $11.765 billion remaining the dominant engine.
- Profitability swung decisively positive: Q2 2026 net income was $3.020 billion (EPS $4.73) versus a Q2 2025 loss of -$4.277 billion (EPS -$8.58), with net margin recovering to 15.21% from -26.06%. The quarterly progression of $2.174 billion in Q1 2026 and $2.134 billion in Q4 2025 shows a business now earning roughly $2-3 billion per quarter.
Bearish
- Severe relative underperformance and downtrend: The stock is down 18.63% year-to-date and 0.69% over the past year, versus the S&P 500's +11.93% YTD and +15.53% one-year returns. Relative strength is negative across every window (-30.56 YTD, -16.22 one-year), and the 31.73% max drawdown confirms this has been a value trap rather than a dip-buying opportunity.
- Trailing profitability metrics remain depressed: Trailing net margin is only 3.54% and operating margin 3.29%, dragged by the Q2 2025 loss and integration charges, while ROE of 2.16% and ROA of 1.52% are far below what a scaled card lender should earn. The gap between quarterly run-rate profitability and trailing ratios must be reconciled for the thesis to hold.
- Consumer credit deterioration risk: Subprime auto delinquencies are at 32-year highs, pressuring riskier lenders and raising the question of whether Capital One's disciplined underwriting is a relative advantage or a warning that loss provisions will stay elevated. With a 0.72 payout ratio and 1.83x interest coverage, there is limited room for error if credit costs rise.
- Messy earnings and integration execution risk: The Q1 2026 estimate miss and acquisition accounting distortions (trailing PE of 60.1x versus forward 8.38x) create an opaque earnings picture that the market is penalizing. The wide analyst target range of $219-$290 (32% spread) reflects genuine uncertainty about synergy realization and credit costs.
COF Technical Analysis
Capital One is in a sustained downtrend that has recently stabilized into a range: the stock is down 0.69% over the past year and 18.63% year-to-date, a stark underperformance versus the S&P 500's +15.53% one-year and +11.93% YTD returns. At $201.74, the shares sit at roughly 32% of the 52-week range of $174.24–$259.64 — closer to the low than the high — which reflects a market that has de-rated the name rather than one chasing momentum; the 31.73% max drawdown confirms this has been a value-trap risk rather than a dip-buying opportunity so far. The stock is nonetheless holding well above its 52-week low, suggesting the selling has found a floor rather than accelerating.
Short-term momentum is flat-to-slightly-negative and diverging from an already weak longer-term trend: the 1-month change is -0.71% and the 3-month change is -3.02%, both worse than the 6-month change of -2.29%, meaning the pace of decline has actually moderated even as absolute performance remains soft. Relative strength is persistently negative across every window — -1.93 over 1 month, -5.71 over 3 months, -16.22 over 1 year, and -30.56 YTD — confirming Capital One is losing ground to the market rather than merely tracking it. The recent price action shows a recovery from the September low near $193 (September 30 close of $193.07) back to $201.74, with the last session up 1.45% on a previous close of $198.86; volume of roughly 4.75 million shares and a short ratio of 2.52 suggest no aggressive bearish positioning, so the drift lower looks like apathy rather than conviction selling.
Key technical levels are well defined: support sits at the 52-week low of $174.24, roughly 13.6% below the current price, while resistance is the 52-week high of $259.64, about 28.7% above — a wide, asymmetric band that gives the stock room to run if sentiment turns. A breakout above the $220–$228 area where the stock repeatedly stalled in August (peaks of $227.34 on August 14 and $223.83 on August 13) would be the first sign of a trend change; a breakdown below $193 would put the $174.24 low in play and likely trigger further de-rating. With a beta of 1.04, Capital One moves roughly in line with the market — only about 4% more volatile than SPY — so position sizing should focus on idiosyncratic credit and integration risk rather than market beta.
Beta
1.04
1.04x market volatility
Max Drawdown
-31.7%
Largest decline past year
52-Week Range
$174-$260
Price range past year
Annual Return
-8.5%
Cumulative gain past year
| Period | COF Return | S&P 500 |
|---|---|---|
| 1m | +2.7% | -1.0% |
| 3m | -0.7% | +2.9% |
| 6m | +5.2% | +6.5% |
| 1y | -8.5% | +13.1% |
| ytd | -18.8% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
COF Fundamental Analysis
Revenue is growing strongly and the trajectory is improving: Q2 2026 revenue was $19.861 billion, up 21.03% year-over-year from $16.410 billion, following $19.317 billion in Q1 2026 (+44.1% YoY versus $13.405 billion) and $19.614 billion in Q4 2025 (+42.0% YoY versus $13.809 billion). The step-change is clearly Discover-driven — quarterly revenue jumped from roughly $13.4–$13.8 billion pre-deal to roughly $19.3–$19.9 billion post-deal — and the segment mix shows credit card at $11.765 billion, consumer banking at $3.209 billion, commercial banking at $0.850 billion, and other at $0.026 billion, meaning cards remain the overwhelming growth engine. The key question for the investment case is organic versus acquired growth: the 21% YoY figure flatters the underlying franchise, and investors should watch whether the $19–20 billion quarterly run-rate expands from cross-sell and network economics rather than simply annualizing the acquisition.
Profitability has swung decisively from a loss to solid earnings: Q2 2026 net income was $3.020 billion (EPS $4.73) versus a Q2 2025 loss of -$4.277 billion (EPS -$8.58), and net margin recovered to 15.21% from -26.06% a year earlier. The quarterly progression — $2.174 billion in Q1 2026, $2.134 billion in Q4 2025, $3.192 billion in Q3 2025 — shows a business earning roughly $2–3 billion per quarter, with Q2's 84.95% gross margin and 36.98% operating margin reflecting the post-acquisition accounting mix. However, the headline trailing figures are distorted: trailing net margin is only 3.54% and operating margin 3.29%, dragged by the Q2 2025 loss and integration charges, while ROE of 2.16% and ROA of 1.52% remain far below what a card lender should earn at scale — the gap between quarterly run-rate profitability and trailing ratios is the single most important thing for investors to reconcile.
Balance-sheet and cash-flow metrics are healthy for a bank but require care: debt-to-equity is 0.449, total debt to capitalization 28.5%, and the company generated $32.199 billion in trailing free cash flow against a $131.0 billion market cap — a free-cash-flow yield of roughly 24.6%, though for a lender this metric is heavily influenced by balance-sheet flows rather than distributable earnings. Q2 2026 operating cash flow was $8.444 billion with $9.0 billion of free cash flow, funding $2.793 billion of buybacks and $573 million of dividends, while cash at period end stood at $62.768 billion. The current ratio of 0.146 looks alarming but is normal for a bank, where deposits and funding are not classified as current liabilities; the more relevant signals are the 1.83x interest coverage and the 0.72 payout ratio, which suggest the dividend is covered but leaves limited room for error if credit costs rise.
Quarterly Revenue
$19.9B
2026-06
Revenue YoY Growth
+21.0%
YoY Comparison
Gross Margin
85.0%
Latest Quarter
Free Cash Flow
$32.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is COF Overvalued?
Because trailing net income is positive but heavily distorted by the 2025 acquisition-related loss, the trailing PE of 60.1x is not meaningful; the appropriate primary metric is the forward PE of 8.38x, which reflects the market's expectation that normalized earnings will be far above the trailing figure. The gap between 60.1x trailing and 8.38x forward is enormous and implies the Street expects earnings to multiply as Discover synergies land — consensus 2027 EPS of $37.23 against a $201.74 price supports that math. The PEG ratio of -0.92 is a mechanical artifact of negative historical growth and should be disregarded.
On the metrics that matter for a bank, Capital One screens cheap: price-to-book of 1.15x, price-to-sales of 1.89x, and EV/EBITDA of 16.52x, with a dividend yield of 1.35%. A 1.15x P/B for a card issuer earning mid-teens returns on tangible capital is a discount to the 1.5–2.0x range typically awarded to high-quality consumer lenders, and the 8.38x forward PE is well below the broader financials sector's mid-teens multiple — a discount of roughly 40–50% that the market is applying for integration risk, credit-cycle exposure, and the messy reported earnings. Whether that discount is justified hinges on whether the $37+ EPS estimate is achievable; if it is, the stock is inexpensive, and if credit deteriorates, book value is the real floor.
Historically, Capital One's own valuation band tells a consistent story: PE ranged from roughly 5x to 25x over the past several years, with the stock trading near 1.0–1.35x book for most of 2024–2026 (P/B of 1.09x in Q2 2026, 1.01x in Q1 2026, 1.35x in Q4 2025, and 0.91x in Q3 2024). At 1.15x book the stock sits in the middle of its own recent range — not a distressed valuation, but far from the premium it commanded in 2021 when P/B exceeded 1.1x on much lower book value. The market is pricing a modest recovery, not optimism, which limits downside if execution merely meets expectations but also means multiple expansion requires visible credit improvement.
PE
60.1x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 5x~20x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the gap between run-rate and trailing profitability. Trailing ROE of 2.16% and ROA of 1.52% are far below what a scaled card lender should earn, and trailing net margin of 3.54% is dragged by the Q2 2025 loss and integration charges. The 0.72 payout ratio and 1.83x interest coverage leave limited cushion if credit costs rise, while the 0.146 current ratio — normal for a bank but still a liquidity signal — means funding depends on deposit stability. Revenue concentration in credit cards ($11.765 billion of $19.861 billion in Q2 2026) means any deterioration in card credit quality flows directly to the bottom line. The $32.199 billion trailing free cash flow and $62.768 billion cash position provide buffer, but for a lender these metrics are heavily influenced by balance-sheet flows rather than distributable earnings.
Market and competitive risks include valuation compression if the Discover integration disappoints. At 8.38x forward PE, the stock already trades at a 40-50% discount to the financials sector, but that discount could widen if 2027 EPS estimates of $37.23 are cut. Subprime auto delinquencies at 32-year highs threaten the consumer banking segment ($3.209 billion revenue), and competitive pressure in card lending from fintechs and other issuers could erode the revenue synergies management is targeting. With a beta of 1.04, Capital One moves roughly in line with the market, so macro-driven sector rotation out of financials would hit the stock proportionally. Recent news highlights that earnings will remain messy due to acquisition costs, and the Q1 2026 estimate miss already triggered a stock drop, showing the market's low tolerance for execution stumbles.
Worst-case scenario: a recession-driven credit cycle combines with Discover integration delays, causing 2027 EPS to fall well short of the $37.23 consensus and forcing provision builds that compress book value. In this scenario, the stock could retest its 52-week low of $174.24, representing a 13.6% decline from the current $201.74, and if book value deteriorates, the 0.91x P/B seen in Q3 2024 could imply further downside toward the $160s. The 31.73% max drawdown already experienced shows the stock's capacity for severe declines. A realistic adverse case is a -13.6% to -20% move to the $174-$161 range, with the analyst low target of $219 providing little downside protection since it assumes modest synergy capture rather than a credit downturn.
FAQ
The most severe risk is consumer credit deterioration: subprime auto delinquencies at 32-year highs could spread to credit card losses, forcing provision builds that erase the earnings recovery, especially with a 0.72 payout ratio and 1.83x interest coverage leaving little cushion. Second is Discover integration execution — the Q1 2026 estimate miss shows how quickly sentiment can sour, and the wide $219-$290 analyst target range reflects genuine uncertainty. Third is valuation compression if 2027 EPS estimates are cut below $36.27, which would invalidate the 8.38x forward PE thesis. Fourth is macro sensitivity: with a beta of 1.04, a sector rotation out of financials would hit the stock proportionally, and the 31.73% max drawdown shows its capacity for severe declines.
The 12-month forecast has three scenarios: a base case (50% probability) targeting $219-$252 as earnings normalize and integration proceeds on schedule, a bull case (30%) targeting $252-$290 if synergies land ahead of plan and the stock re-rates toward 1.3-1.5x book, and a bear case (20%) targeting $174-$219 if a credit downturn or integration stumble forces provision builds. The base case is most likely, assuming 2027 EPS tracks within the $36.27-$37.99 consensus range and Discover cost synergies are realized without major charges. The key assumption is that consumer credit conditions remain stable with no severe recession.
COF appears undervalued on forward metrics: the 8.38x forward PE is well below the financials sector's mid-teens multiple, and 1.15x price-to-book is below the 1.5-2.0x range for high-quality consumer lenders. The trailing PE of 60.1x is distorted by the 2025 acquisition-related loss and should be disregarded. Relative to its own history, the stock sits mid-range of its 2024-2026 P/B band of 0.91x-1.35x, so it is not distressed but far from premium. The market is pricing a modest recovery, not optimism — the discount implies skepticism about the $37.23 2027 EPS consensus, and if that estimate is achieved, the stock is inexpensive.
From a risk/reward perspective, COF offers 25.0% upside to the average analyst target of $252.27 and 8.6% upside even to the lowest target of $219, with all 22 analysts holding targets above the current price. The valuation is compelling at 8.38x forward earnings and 1.15x book, a 40-50% discount to financials peers. However, the biggest downside risk is a credit downturn that could retest the 52-week low of $174.24, a 13.6% decline. This makes it a good buy for patient value investors with a 12-18 month horizon who can tolerate volatility and believe in the Discover synergy story, but less suitable for risk-averse investors or those needing near-term performance given the 18.63% YTD decline.
COF is better suited for a medium-to-long-term holding period of 12-18 months rather than short-term trading. The thesis depends on the Discover integration playing out through 2027, with consensus EPS of $37.23 requiring time to materialize, and the stock's 31.73% max drawdown and 18.63% YTD decline show high near-term volatility that could stop out short-term traders. The 1.35% dividend yield is modest and not a reason to hold alone, but the 0.72 payout ratio suggests it is sustainable. Earnings visibility is improving with the tight analyst EPS range of $36.27-$37.99, but the messy acquisition accounting means quarterly results will remain volatile — patient investors who can look through the noise are best positioned.